Molecular mechanism of peroxisome proliferator-activated receptor α activation by WY14643: A new mode of ligand recognition and receptor stabilization

Journal of Molecular Biology

Volumn 425, Issue 16, 2013, Pages 2878-2893

  Bernardes, Amanda ^a   Souza, Paulo C T ^b   Muniz, João R C ^a   Ricci, Clarisse G ^b   Ayers, Stephen D ^c   Parekh, Nili M ^d   Godoy, André S ^a   Trivella, Daniela B B ^e   Reinach, Peter ^d   Webb, Paul ^c   Skaf, Munir S ^b   Polikarpov, Igor ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF CAMPINAS   (Brazil)

^c HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^d STATE UNIVERSITY OF NEW YORK   (United States)

^e National Center for Research in Energy and Materials   (Brazil)

Author keywords

crystal structure; dry eye disease; molecular dynamics; PPAR ; protein and ligand interaction

Indexed keywords

FIBRIC ACID DERIVATIVE; GW 6471; INTERLEUKIN 6; INTERLEUKIN 8; OXYGEN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ANTAGONIST; PIRINIXIC ACID; UNCLASSIFIED DRUG;

ARTICLE; ATOM; BINDING AFFINITY; CORNEA EPITHELIUM; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHOBICITY; HYPEROSMOTIC STRESS; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; WILD TYPE;

EID: 84880923648     PISSN: 00222836     EISSN: 10898638     Source Type: Journal    
DOI: 10.1016/j.jmb.2013.05.010     Document Type: Article

References (79)

1. J. Berger, and D.E. Moller The mechanisms of action of PPARs Annu. Rev. Med. 53 2002 409 435 (Pubitemid 34177889)
2. J.T. Moore, J.L. Collins, and K.H. Pearce The nuclear receptor superfamily and drug discovery ChemMedChem 1 2006 504 523 (Pubitemid 43759761)
3. Y. Brélivet, N. Rochel, and D. Moras Structural analysis of nuclear receptors: from isolated domains to integral proteins Mol. Cell. Endocrinol. 348 2011 466 473
4. V. Perissi, and M.G. Rosenfeld Controlling nuclear receptors: the circular logic of cofactor cycles Nat. Rev., Mol. Cell Biol. 6 2005 542 554 (Pubitemid 40943045)
5. Y.A. Bulynko, and B.W. O'Malley Nuclear receptor coactivators: structural and functional biochemistry Biochemistry 50 2010 313 328
6. L. Michalik, J. Auwerx, J. Berger, V. Chatterjee, C. Glass, and F. Gonzalez International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors Pharmacol. Rev. 58 2006 726 741 (Pubitemid 44833742)
7. F. Filip-Ciubotaru, L. Foia, C. Manciuc, and C. Grigore PPARs: structure, mechanisms of action and control. Note I Rev. Med.-Chir. Soc. Med. Nat. Iasi 115 2011 477 484
8. C. Duval, M. Müller, and S. Kersten PPARα and dyslipidemia Biochim. Biophys. Acta 1771 2007 961 971
9. D.H. van Raalte, M. Li, P.H. Pritchard, and K.M. Wasan Peroxisome proliferator-activated receptor (PPAR)-α: a pharmacological target with a promising future Pharmacol. Res. 21 2004 1531 1538 (Pubitemid 41184380)
10. F. Lannutti, A. Marrone, and N. Re Prediction of the PPARα agonism of fibrates by combined MM-docking approaches J. Mol. Graphics Modell. 29 2011 865 875
11. W. Bourguet, P. Germain, and H. Gronemeyer Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications Trends Pharmacol. Sci. 21 2000 381 388
12. S.P. Samarasinghe, M.M. Sutanto, A.M. Danos, D.N. Johnson, M.J. Brady, and R.N. Cohen Altering PPARγ ligand selectivity impairs adipogenesis by thiazolidinediones but not hormonal inducers Obesity (Silver Spring) 17 2009 965 972
13. B. Kota, T. Huang, and B. Roufogalis An overview on biological mechanisms of PPARs Pharmacol. Res. 51 2005 85 94 (Pubitemid 40040538)
14. B. Desvergne, and W. Wahli Peroxisome proliferator-activated receptors: nuclear control of metabolism Endocr. Rev. 20 1999 649 688 (Pubitemid 30650602)
15. S. Kersten, B. Desvergne, and W. Wahli Roles of PPARs in health and disease Nature 405 2000 421 424 (Pubitemid 30367411)
16. B. Staels, M. Maes, and A. Zambon Fibrates and future PPARα agonists in the treatment of cardiovascular disease Nat. Clin. Pract. Cardiovasc. Med. 5 2008 542 553
17. S.M. Grundy, G.L. Vega, Z. Yuan, W.P. Battisti, W.E. Brady, and J. Palmisano Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial) Am. J. Cardiol. 95 2005 462 468 (Pubitemid 40247539)
18. J. Li, L.J. Kennedy, Y. Shi, S. Tao, X.Y. Ye, and S.Y. Chen Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor α selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl) (methoxycarbonyl)amino)acetic acid (BMS-687453) J. Med. Chem. 53 2010 2854 2864
19. A.A. Santilli, A.C. Scotese, and R.M. Tomarelli A potent antihypercholesterolemic agent: (4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio) acetic acid (Wy-14643) Experientia 30 1974 1110 1111
20. J.K. Reddy, J.R. Warren, M.K. Reddy, and N.D. Lalwani Hepatic and renal effects of peroxisome proliferators: biological implications Ann. N. Y. Acad. Sci. 386 1982 81 110 (Pubitemid 12036588)
21. E. Briguglio, R. Di Paola, I. Paterniti, E. Mazzon, G. Oteri, G. Cordasco, and S. Cuzzocrea WY-14643, a potent peroxisome proliferator activator receptor-α PPAR-α agonist ameliorates the inflammatory process associated to experimental periodontitis PPAR Res. 2010 2010 193019
22. P. Delerive, J.C. Fruchart, and B. Staels Peroxisome proliferator- activated receptors in inflammation control J. Endocrinol. 169 2001 453 459 (Pubitemid 32536978)
23. R. Kleemann, L. Verschuren, B.J. de Rooij, J. Lindeman, M.M. de Maat, and A.J. Szalai Evidence for anti-inflammatory activity of statins and PPARα activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro Blood 103 2004 4188 4194 (Pubitemid 38685361)
24. P.R. Devchand, H. Keller, J.M. Peters, M. Vazquez, F.J. Gonzalez, and W. Wahli The PPARα-leukotriene B4 pathway to inflammation control Nature 384 1996 39 43
25. S. Saika Yin and yang in cytokine regulation of corneal wound healing: roles of TNF-α Cornea 26 2007 S70 S74
26. J.Z. Zhang, and K.W. Ward WY-14 643, a selective PPARα agonist, induces proinflammatory and proangiogenic responses in human ocular cells Int. J. Toxicol. 29 2010 496 504
27. A. Bonazzi, V. Mastyugin, P.A. Mieyal, M.W. Dunn, and M. Laniado-Schwartzman Regulation of cyclooxygenase-2 by hypoxia and peroxisome proliferators in the corneal epithelium J. Biol. Chem. 275 2000 2837 2844 (Pubitemid 30082057)
28. R. Nolte, G. Wisely, S. Westin, J. Cobb, M. Lambert, and R. Kurokawa Ligand binding and co-activator assembly of the peroxisome proliferator- activated receptor-γ Nature 395 1998 137 143 (Pubitemid 28425645)
29. P.D. Adams, P.V. Afonine, G. Bunkóczi, V.B. Chen, I.W. Davis, and N. Echols PHENIX: a comprehensive Python-based system for macromolecular structure solution Acta Crystallogr., Sect. D: Biol. Crystallogr. 66 2010 213 221
30. U. Grether, A. Bénardeau, J. Benz, A. Binggeli, D. Blum, and H. Hilpert Design and biological evaluation of novel, balanced dual PPARα/γ agonists ChemMedChem 4 2009 951 956
31. H.E. Xu, M.H. Lambert, V.G. Montana, K.D. Plunket, L.B. Moore, and J.L. Collins Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors Proc. Natl Acad. Sci. USA 98 2001 13919 13924 (Pubitemid 33115999)
32. A. Bénardeau, J. Benz, A. Binggeli, D. Blum, M. Boehringer, and U. Grether Aleglitazar, a new, potent, and balanced dual PPARα/γ agonist for the treatment of type II diabetes Bioorg. Med. Chem. Lett. 19 2009 2468 2473
33. J.M. Lehmann, J.M. Lenhard, B.B. Oliver, G.M. Ringold, and S.A. Kliewer Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs J. Biol. Chem. 272 1997 3406 3410
34. M.H. Hsu, C.N. Palmer, K.J. Griffin, and E.F. Johnson A single amino acid change in the mouse peroxisome proliferator-activated receptor α alters transcriptional responses to peroxisome proliferators Mol. Pharmacol. 48 1995 559 567
35. J.M. Shipley, C.H. Hurst, S.S. Tanaka, F.L. DeRoos, J.L. Butenhoff, A.M. Seacat, and D.J. Waxman trans-activation of PPARα and induction of PPARα target genes by perfluorooctane-based chemicals Toxicol. Sci. 80 2004 151 160 (Pubitemid 38967406)
36. J. Lo Verme, J. Fu, G. Astarita, G. La Rana, R. Russo, A. Calignano, and D. Piomelli The nuclear receptor peroxisome proliferator-activated receptor-α mediates the anti-inflammatory actions of palmitoylethanolamide Mol. Pharmacol. 67 2005 15 19 (Pubitemid 40069962)
37. L. Jin, S. Lin, H. Rong, S. Zheng, S. Jin, R. Wang, and Y. Li Structural basis for iloprost as a dual peroxisome proliferator-activated receptor α/δ agonist J. Biol. Chem. 286 2011 31473 31479
38. O. Rau, Y. Syha, H. Zettl, M. Kock, A. Bock, and M. Schubert-Zsilavecz α-Alkyl substituted pirinixic acid derivatives as potent dual agonists of the peroxisome proliferator activated receptor α and γ Arch. Pharm. (Weinheim, Ger.) 341 2008 191 195
39. M.L. Sierra, V. Beneton, A.B. Boullay, T. Boyer, A.G. Brewster, and F. Donche Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARα agonists. 1. Discovery of a novel series of potent HDLc raising agents J. Med. Chem. 50 2007 685 695 (Pubitemid 46332981)
40. P. Cronet, J.F. Petersen, R. Folmer, N. Blomberg, K. Sjöblom, and U. Karlsson Structure of the PPARα and -γ ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family Structure 9 2001 699 706 (Pubitemid 32772892)
41. W. Wang, P. Devasthale, D. Farrelly, L. Gu, T. Harrity, and M. Cap Discovery of azetidinone acids as conformationally-constrained dual PPARα/γ agonists Bioorg. Med. Chem. Lett. 18 2008 1939 1944 (Pubitemid 351380888)
42. T. Oyama, K. Toyota, T. Waku, Y. Hirakawa, N. Nagasawa, and J.I. Kasuga Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures Acta Crystallogr., Sect. D: Biol. Crystallogr. 65 2009 786 795
43. H. Oon Han, S.H. Kim, K.H. Kim, G.C. Hur, H. Joo Yim, and H.K. Chung Design and synthesis of oxime ethers of α-acyl-β-phenylpropanoic acids as PPAR dual agonists Bioorg. Med. Chem. Lett. 17 2007 937 941 (Pubitemid 46188533)
44. A. Ambrosio, S. Dias, I. Polikarpov, R. Zurier, S. Burstein, and R. Garratt Ajulemic acid, a synthetic nonpsychoactive cannabinoid acid, bound to the ligand binding domain of the human peroxisome proliferator-activated receptor γ J. Biol. Chem. 282 2007 18625 18633 (Pubitemid 47100214)
45. A.A. Amato, S. Rajagopalan, J.Z. Lin, B.M. Carvalho, A.C. Figueira, and J. Lu GQ-16, a novel peroxisome proliferator-activated receptor γ (PPARγ) ligand, promotes insulin sensitization without weight gain J. Biol. Chem. 287 2012 28169 28179
46. M.V. Liberato, A.S. Nascimento, S.D. Ayers, J.Z. Lin, A. Cvoro, and R.L. Silveira Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonists PLoS One 7 2012 e36297
47. L. Martínez, I. Polikarpov, and M.S. Skaf Only subtle protein conformational adaptations are required for ligand binding to thyroid hormone receptors: simulations using a novel multipoint steered molecular dynamics approach J. Phys. Chem. B 112 2008 10741 10751
48. R.L. Silveira, J. Martínez, M.S. Skaf, and L. Martínez Enzyme microheterogeneous hydration and stabilization in supercritical carbon dioxide J. Phys. Chem. B 116 2012 5671 5678
49. W. Berrabah, P. Aumercier, P. Lefebvre, and B. Staels Control of nuclear receptor activities in metabolism by post-translational modifications FEBS Lett. 585 2011 1640 1650
50. Z. Pan, Z. Wang, H. Yang, F. Zhang, and P.S. Reinach TRPV1 activation is required for hypertonicity-stimulated inflammatory cytokine release in human corneal epithelial cells Invest. Ophthalmol. Visual Sci. 52 2011 485 493
51. K.S. Na, J.W. Mok, J.Y. Kim, C.R. Rho, and C.K. Joo Correlations between tear cytokines, chemokines, and soluble receptors and clinical severity of dry eye disease Invest. Ophthalmol. Visual Sci. 53 2012 5443 5450
52. L. Martínez, A.S. Nascimento, F.M. Nunes, K. Phillips, R. Aparicio, and S.M. Dias Gaining ligand selectivity in thyroid hormone receptors via entropy Proc. Natl Acad. Sci. USA 106 2009 20717 20722
53. L. Bleicher, R. Aparicio, F.M. Nunes, L. Martinez, S.M. Gomes Dias, and A.C. Figueira Structural basis of GC-1 selectivity for thyroid hormone receptor isoforms BMC Struct. Biol. 8 2008 8
54. J.B. Bruning, M.J. Chalmers, S. Prasad, S.A. Busby, T.M. Kamenecka, and Y. He Partial agonists activate PPARγ using a helix 12 independent mechanism Structure 15 2007 1258 1271 (Pubitemid 47539157)
55. T. Waku, T. Shiraki, T. Oyama, Y. Fujimoto, K. Maebara, and N. Kamiya Structural insight into PPARγ activation through covalent modification with endogenous fatty acids J. Mol. Biol. 385 2009 188 199
56. T. Waku, T. Shiraki, T. Oyama, and K. Morikawa Atomic structure of mutant PPARγ LBD complexed with 15d-PGJ2: novel modulation mechanism of PPARγ/RXRα function by covalently bound ligands FEBS Lett. 583 2009 320 324
57. A.C. Puhl, A. Bernardes, R.L. Silveira, J. Yuan, J.L. Campos, and D.M. Saidemberg Mode of peroxisome proliferator-activated receptor γ activation by luteolin Mol. Pharmacol. 81 2012 788 799
58. A. Blondel, J.P. Renaud, S. Fischer, D. Moras, and M. Karplus Retinoic acid receptor: a simulation analysis of retinoic acid binding and the resulting conformational changes J. Mol. Biol. 291 1999 101 115 (Pubitemid 29391408)
59. P. Carlsson, S. Burendahl, and L. Nilsson Unbinding of retinoic acid from the retinoic acid receptor by random expulsion molecular dynamics Biophys. J. 91 2006 3151 3161 (Pubitemid 44788250)
60. L. Martínez, P. Webb, I. Polikarpov, and M.S. Skaf Molecular dynamics simulations of ligand dissociation from thyroid hormone receptors: evidence of the likeliest escape pathway and its implications for the design of novel ligands J. Med. Chem. 49 2006 23 26 (Pubitemid 43077316)
61. L. Martínez, M.T. Sonoda, P. Webb, J.D. Baxter, M.S. Skaf, and I. Polikarpov Molecular dynamics simulations reveal multiple pathways of ligand dissociation from thyroid hormone receptors Biophys. J. 89 2005 2011 2023 (Pubitemid 41233556)
62. D. Genest, N. Garnier, A. Arrault, C. Marot, L. Morin-Allory, and M. Genest Ligand-escape pathways from the ligand-binding domain of PPARγ receptor as probed by molecular dynamics simulations Eur. Biophys. J. 37 2008 369 379 (Pubitemid 351423112)
63. A. Leslie The integration of macromolecular diffraction data Acta Crystallogr., Sect. D: Biol. Crystallogr. 62 2006 48 57
64. Collaborative Computational Project, N. m The CCP4 suite: programs for protein crystallography Acta Crystallogr., Sect. D: Biol. Crystallogr. 50 1994 760 763
65. P. Adams, R. Grosse-Kunstleve, L. Hung, T. Ioerger, A. McCoy, and N. Moriarty PHENIX: building new software for automated crystallographic structure determination Acta Crystallogr., Sect. D: Biol. Crystallogr. 58 2002 1948 1954 (Pubitemid 35337293)
66. P. Emsley, and K. Cowtan Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 60 2004 2126 2132 (Pubitemid 41742764)
67. F.A. Batista, D.B. Trivella, A. Bernardes, J. Gratieri, P.S. Oliveira, and A.C. Figueira Structural insights into human peroxisome proliferator activated receptor δ (PPAR-δ) selective ligand binding PLoS One 7 2012 e33643
68. C. Yuan, J.Z. Lin, D.H. Sieglaff, S.D. Ayers, F. Denoto-Reynolds, J.D. Baxter, and P. Webb Identical gene regulation patterns of T3 and selective thyroid hormone receptor modulator GC-1 Endocrinology 153 2012 501 511
69. W. Humphrey, A. Dalke, and K. Schulten VMD: visual molecular dynamics J. Mol. Graphics 14 1996 27 28
70. as and adding missing hydrogens to macromolecules Nucleic Acids Res. 33 2005 W368 W371
71. L. Verlet Computer experiments on classical fluids. I Thermodinamical properties of Lennard-Jones molecules Phys. Rev. 21 1967 1531 1538
72. T. Darden, D. York, and L. Pedersen Particle mesh Ewald: an N-log(N) method for Ewald sums in large systems J. Chem. Phys. 98 1993 10089 10092
73. J.C. Phillips, R. Braun, W. Wang, J. Gumbart, E. Tajkhorshid, and E. Villa Scalable molecular dynamics with NAMD J. Comput. Chem. 26 2005 1781 1802 (Pubitemid 43078511)
74. A.D. MacKerell, D. Bashford, M. Bellott, R.L. Dunbrack, J.D. Evanseck, and M.J. Field All-atom empirical potential for molecular modeling and dynamics studies of proteins J. Phys. Chem. B 102 1998 3586 3616 (Pubitemid 128576688)
75. W.L. Jorgensen, J. Chandrasekhar, J.D. Madura, R.W. Impey, and M.L. Klein Comparison of single potential functions for simulating liquid water J. Chem. Phys. 79 1983 926 935
76. A. Hansson, P.C.T. Souza, R.L. Silveira, L. Matínez, and M.S. Skaf CHARMM force field parameterization of roziglitazone Int. J. Quantum Chem. 111 2011 1346 1354
77. É.T. Prates, P.C.T. Souza, M. Pickholz, and M.S. Skaf CHARMM-based parameterization of neutral articaine - a widely used local anesthetic Int. J. Quantum Chem. 111 2011 1339 1345
78. A. Amadei, A.B.M. Linssen, and H.J.C. Berendsen Essential dynamics of proteins Proteins: Struct., Funct., Bioinf. 17 2004 412 425
79. K. Araki-Sasaki, Y. Ohashi, T. Sasabe, K. Hayashi, H. Watanabe, Y. Tano, and H. Handa An SV40-immortalized human corneal epithelial cell line and its characterization Invest. Ophthalmol. Visual Sci. 36 1995 614 621